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ABSTRACT
Systemic mastocytosis are rare neoplasms characterized by accumulation of mast 
cells in at least one internal organ. The majority of systemic mastocytosis patients 
carry KIT D816V mutation, which activates constitutively the KIT receptor. Patient with 
advanced forms of systemic mastocytosis, such as aggressive systemic mastocytosis 
or mast cell leukemia, are poorly treated to date. Unfortunately, the lack of in vivo 
models reflecting KIT D816V+ advanced disease hampers pathophysiological studies 
and preclinical development of new therapies for such patients. Here, we describe 
a new in vivo model of KIT D816V+ advanced systemic mastocytosis developed by 
transplantation of the human ROSAKIT D816V-Gluc mast cell line in NOD-SCID IL-2R g-/- mice, 
using Gaussia princeps luciferase as a reporter. Intravenous injection of ROSAKIT D816V-Gluc 
cells led, in 4 weeks, to engraftment in all injected primary recipient mice. Engrafted 
cells were found at high levels in bone marrow, and at lower levels in spleen, liver and 
peripheral blood. Disease progression was easily monitored by repeated quantification 
of Gaussia princeps luciferase activity in peripheral blood. This quantification evidenced 
a linear relationship between the number of cells injected and the neoplastic mast cell 
burden in mice. Interestingly, the secondary transplantation of ROSAKIT D816V-Gluc cells 
increased their engraftment capability. To conclude, this new in vivo model mimics 
at the best the features of human KIT D816V+ advanced systemic mastocytosis. In 
addition, it is a unique and convenient tool to study the kinetics of the disease and the 
potential in vivo activity of new drugs targeting neoplastic mast cells.
INTRODUCTION
Human mast cells (MCs) are non-circulating, 
tissue-resident cells derived from CD34+ hematopoietic 
stem cells in the bone marrow (BM) [1]. Mature MCs 
are found in most vascularized organs, surrounding blood 
vessels and nerves [2]. MC and their progenitors express 
the receptor for stem cell factor (SCF), KIT (CD117), a 
transmembrane type III tyrosine kinase receptor (RTK) 
[3]. Binding of SCF to KIT governs most if not all the 
aspects of human MC biology, from proliferation to 
differentiation, migration, activation and survival [4, 5].
Mastocytosis are a heterogeneous group of diseases 
characterized by accumulation of abnormal (neoplastic) 
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MCs in one or several organs, affecting both children and 
adults [6]. In adults, most patients present with a systemic 
involvement (systemic mastocytosis; SM). According to 
the World Health Organization (WHO), SM is classified 
into four major categories. Indolent SM (ISM) has a good 
prognosis, usually requires only symptomatic therapies, 
and ISM patients have a nearly normal life expectancy 
[6, 7]. The three other categories, collectively termed 
advanced SM, share a poor prognostic. Advanced SM 
categories include SM with an associated hematologic 
neoplasm (SM-AHN), aggressive SM (ASM), and 
MC leukemia (MCL) [8]. All categories of SM are 
characterized by an accumulation of abnormal MCs in BM 
and in other extra-cutaneous organs [9, 10].
WHO criteria for the diagnostic of SM include one 
major criterion and four minor criteria. The diagnosis 
of SM is established if at least the major and one minor 
criterion or at least three minor criteria are fulfilled [8, 
11]. The major diagnostic criterion is defined by the 
presence of aggregates of at least 15 MCs identified by 
tryptase staining in BM and/or other extra-cutaneous 
organ biopsies. Minor criterions are: i) presence of 25% 
MCs with atypical morphology in BM smears [12], ii) 
aberrant immunophenotype of MCs (expression of CD2 
and/or CD25) [13], iii) presence of an activating point 
mutation in codon 816 of the KIT gene in BM, peripheral 
blood (PB) or other extracutaneous organs [14, 15], and iv) 
increased level of serum tryptase (> 20 ng/mL) [16]. If SM 
is diagnosed, the next step is to evaluate its aggressiveness 
according to the presence of B-findings (borderline benign) 
and C-finding (consider cytoreduction). B- and C-findings 
correspond respectively to high MC burden and to organ 
dysfunction leading to the use of cytoreductive therapy [7]. 
The absence of B- and C-findings reflects an ISM [6, 7]. 
By contrast, the presence of at least one C-findings directs 
the diagnosis towards an advanced form of SM (ASM, 
SM-AHN or MCL). ASM is diagnosed when MCs in BM 
smears represent less than 20% of total nucleated cells [8, 
17]. MCL is diagnosed when MCs in BM smears represent 
> 20% of total nucleated cells (with or without circulating 
neoplastic MCs in the bloodstream) [8, 17].
KIT is crucially involved in the pathophysiology 
of SM as the majority of patients carry KIT mutations, 
notably KIT D816V [18]. This mutation, found in > 85% 
of all patients with SM, activates constitutively KIT [15]. 
Activated KIT induces sustained proliferative and anti-
apoptotic signaling in neoplastic MCs [18]. This KIT 
mutant receptor is resistant to most type I tyrosine kinase 
inhibitors (TKIs) targeting the wild-type receptor (KIT WT), 
such as imatinib [19]. By contrast, the mutant is sensitive to 
multikinase inhibitors such as midostaurin (PKC412) [20]. 
Thus, midostaurin is currently under clinical trials to treat 
Advanced SM [21]. However, this drug seems not sufficient 
to induce long-lasting complete responses in ASM and 
MCL [21]. There is thus a need to identify novel therapies 
for these diseases. To this purpose, relevant preclinical in 
vivo models of SM may be very useful. Unfortunately, the 
present lack of in vivo models mimicking at the best human 
KIT D816V+ advanced SM hampers pathophysiological 
studies and the development of new therapeutics. Only a 
few mouse models have been previously developed. In 2005, 
Zappulla et al. described a transgenic murine model using 
the primate chymase promoter as a driver of human KIT 
D816V mutation [22]. The authors reported the development 
of a SM-like disease within 12 to 24 months in only 30% 
of transgenic mice [22]. A few years after, Gerbaulet et al. 
described another transgenic mouse model expressing kit 
D814V mutation (murine homolog to human KIT D816V) 
[23]. However, this model has a limited utility because of 
the variety of diseases observed, ranging from perinatal 
lethality to pure MC hyperplasia, and of a very long period 
of latency (52 weeks) [23]. Besides, two xenograft mouse 
models have been described: one consisted in the injection 
of the leukemic HMC-1.2 cell line in SCID mice, giving 
rise to solid tumors [24], while the second consisted in 
injecting P815 mastocytoma cells in DBA-2 mice [25]. In 
this latter model, a severe mortality was observed within 9 
days in injected animals [25]. These models are not useful 
for preclinical studies because of drawbacks such as the low 
incidence of disease and/or the kinetic of disease appearance 
and progression, which is either very short or too long. Thus, 
to date, no relevant in vivo models of KIT D816V+ advanced 
SM are available. In addition, none of the existing models 
allows monitoring of disease progression in real time.
We have recently reported on a new tumorigenic 
KIT D816V+ human MC line, termed ROSAKIT D816V, 
which presents most of the characteristics of neoplastic 
MCs found in ASM/MCL [26]. ROSAKIT D816V cell 
line was obtained by stable lentiviral transfection of 
a construct encoding for the KIT D816V mutant gene 
in the parental, non tumorigenic human mast cell line, 
ROSA KIT wild-type (ROSAKIT WT) [26]. In the present 
study, we have stably transduced ROSAKIT D816V cells 
with a construct encoding the naturally secreted Gaussia 
princeps luciferase (Gluc). This allowed us to obtain a 
new human neoplastic MC line, termed ROSAKIT D816V-
Gluc. Gluc reporter is a highly sensitive luciferase allowing 
simultaneously the quantification of cells engraftment 
by measuring its activity in peripheral blood (PB) and in 
vivo imaging system (IVIS) [27]. ROSAKIT D816V-Gluc cells 
were then injected in NOD-SCID IL-2R γ-/- (NSG) mice, 
giving rise to a unique humanized in vivo model of KIT 
D816V+ advanced SM. In this model, disease progression 
and localization of neoplastic MCs were monitored in vivo 
and ex vivo using Gluc as a reporter [27].
RESULTS
Generation and characterization of 
ROSAKIT D816V-Gluc cells secreting luciferase
We transduced the human ROSAKIT D816V MC line 
stably expressing the KIT D816V mutant and GFP [26] 
with a lentiviral vector expressing Gluc and CFP, LV-
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Gluc-CFP. Cells expressing Gluc (ROSAKIT D816V-Gluc cells) 
were sorted by selection of GFP+/CFP+ cells (Figure 1A) 
and cultured in the same medium than their parental 
cell line. As shown in Figure 1B, the introduction of the 
lentiviral vector expressing Gluc and CFP into ROSAKIT 
D816V cells did not induce a significant change in their 
proliferation rate. In addition, the transduction did not 
change the phenotypic characteristics of the cells, as 
evidenced by the similar morphology of ROSAKIT D816V 
and ROSAKIT D816V-Gluc cells when observed on cytospin 
preparation after May Grünwald Giemsa (MGG) staining 
(Figure 1C). In addition, both cell lines expressed equally 
KIT (CD117) (Figure 1D). Besides, allele specific RT-PCR 
experiments confirmed that the two MC lines expressed 
the KIT D816V mutant at the same level (Figure 2A). Of 
note, as already described for ROSAKIT D816V cells [26], 
the KIT receptor was constitutively phosphorylated in 
ROSAKIT D816V-Gluc cells in the absence of SCF (Figure 2B). 
This level of phosphorylation was comparable in the two 
KIT D816V+ MC lines, and slightly higher in ROSAKIT WT 
cells stimulated by SCF (Figure 2B). We then determined 
the level of Gluc activity in the cell-free supernatants 
of both KIT D816V+ cell lines cultured at various 
concentrations, using the Gluc substrate coelenterazine 
(CTZ). Gluc acitivity was detected at a significant level 
in ROSAKIT D816V-Gluc cells supernatants after 24h of 
incubation, even at low cell concentrations (102 cells per 
mL). As expected, there was no Gluc activity detectable in 
ROSAKIT D816V cell supernatants, at any cell concentration 
(Figure 2C). Moreover, we observed that increasing the 
number of ROSAKIT D816V-Gluc cells increased Gluc activity 
in a virtually linear manner (Figure 2C). Finally, in order 
to demonstrate that the transduction of by LV-Gluc-CFP 
did not change the sensitivity of the cells to TKIs, we 
Figure 1: Generation of ROSAKIT D816V-Gluc cell line and comparison with the parental ROSAKIT D816V cell line. A. ROSAKIT 
D816V-Gluc GFP+/CFP+ sorted cells using flow cytometry. B. Comparison of ROSAKIT D816V and ROSAKIT D816V-Gluc cell proliferation by the use of 
the MTT method. Cells were seeded in 96-well plate for 5 days (1 plate/day). At each day (d0 - d4), 20 μL of MTT were added in each well 
and the cells were incubated for 3 additional hours at 37°C. After adding 100 μL of acidified isopropanol, the number of living cells was 
measured for each condition by reading the absorbance at 570 nm. Data are presented as the mean ± SD (n = 3). C. Phenotypic comparison 
of the cytological aspect of ROSAKIT D816V and ROSAKIT D816V-Gluc. MGG-stained cytospin preparations of ROSAKIT D816V (left panel) and 
ROSAKIT D816V-Gluc (right panel). Magnification is x50 (top), x100 (bottom). D. Comparative expression of CD117 (KIT) by in ROSAKIT D816V 
(left) and ROSAKIT D816V-Gluc (right) analyzed by flow cytometry.
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assessed the effects of Imatinib or of Midostaurin on the 
proliferation of both KIT D816V+ cell lines. As expected, 
both cell lines were equally resistant to Imatinib (Figure 
2D) and similarly sensitive to the antiproliferative effects 
of Midostaurin. The IC50 for Midostaurin was found at 70 
nM for ROSAKIT D816V cells and at 94 nM for ROSAKIT D816V-
Gluc cells (Figure 2E).
Analysis of the level of engraftment of ROSAKIT 
D816V-Gluc cells in vivo in NSG mice
Various amounts of ROSAKIT D816V-Gluc cells were 
injected intravenously in irradiated NSG mice. We then 
measured Gluc activity in the plasma of grafted mouse 
four, eight and ten weeks after cell injection. Interestingly, 
at 4 weeks of engraftment, the Gluc activity in plasma 
was found linearly increased in relationship with 
increasing numbers of injected cells (R2 = 0.97) (Figure 
3A). However, although Gluc activity increased in a 
time-dependent manner, there was no apparent difference 
between groups injected with 5x106 or 10x106 cells at 
8 and 10 weeks (Figure 3A). Compared with the level 
of Gluc activity determined in plasma, Gluc intensity 
measured after 10 weeks of engraftment by IVIS was 
found heterogeneous among groups, particularly in the 
groups injected with 5x106 or 10x106 cells at 10 weeks 
(Figure 3B and 3C).
Figure 2: Effects of transduction of ROSAKIT D816V cells with LV-Gluc-CFP on KIT activation and response to TKIs. A. 
Analysis of KIT D816V gene expression in ROSAKIT D816V-Gluc cell line using agarose gel electrophoresis of conventional RT-PCR products. 
Reactions were compared to the levels of expression of mRNA for HPRT. The image is an inverted form of the original picture. B. Detection 
of spontaneous phosphorylation of KIT receptor by western blotting in ROSAKIT D816V-Gluc. Cell lysates from ROSAKIT WT cells stimulated 
with SCF, or from unstimulated ROSAKIT D816V and ROSAKIT D816V-Gluc cells, were subjected to electrophoresis and stained with antibody 
against p-KIT Y719. An anti-human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. The lanes were 
run on the same gel. C. Gluc activity in cell culture supernatants of ROSAKIT D816V (grey line) and ROSAKIT D816V-Gluc (black line). Signals 
were calculated as RLU; relative luminescent units. Data present the mean ± SD (n = 3). D, E. Effect of Imatinib or Midostaurin on the 
proliferation of ROSAKIT D816V (grey line) and ROSAKIT D816V-Gluc cells (black line). Each cell lines were seeded for 72h in 96-well plate in the 
presence of various concentrations (0.001 - 10 μM) of Imatinib (D) or Midostaurin (E). Data are presented as the mean ± SD (n = 3) and are 
expressed as percent of proliferation in each condition relative to the control (untreated cells) considered as 100% proliferation.
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To further investigate the disease progression in 
the three groups of xenografted mice, PB samples were 
analyzed for the presence of ROSAKIT D816V-Gluc cells by 
quantifying the percentage of hCD45+/hCD117+ cells 
using flow cytometry. The percentage of ROSAKIT D816V-
Gluc cells in PB was found very low at 4 weeks (around 
0.007 % in the 1x106 cells group, 0.12 % in the 5x106 
cells group and 0.17% in the 10x106 cells group). This 
percentage increased at 10 weeks in a dose (slightly 
> 0.45% in the 1x106 cells group, > 1 % in the 5x106 
cells group and 1.5 % in the 10x106 cells group at 10 
weeks) and time-dependent manner (Figure 4A). The 
same phenomenon was observed when calculating the 
absolute numbers of ROSAKIT D816V-Gluc cells in PB at 
different time periods and after injection of different 
numbers of cells (Table 1).
Engraftment of ROSAKIT D816V-Gluc cells in vivo in 
NSG mice leads to an advanced SM phenotype
To evaluate the level of ROSAKIT D816V-Gluc cells 
engraftment in BM and spleen, thus the severity of 
the disease, mice (n=3 per group) were euthanized in 
each group 10 weeks after engraftment. BM cells were 
counted and the percentage of hCD45+/CD117+ cells 
was determined in each group. As expected, and in line 
with the human situation for ASM/MCL, the percentage 
of ROSAKIT D816V-Gluc cells in BM was found much higher 
(around 22 %) than in spleen (1.1 %) and in PB (1.0 %). 
There was no difference in cell percentages between the 
three groups of mice in BM as well as in spleen (Figure 
4B and 4C, respectively) and this was confirmed by 
calculation of the absolute number of ROSAKIT D816V-
Figure 3: Monitoring of ROSAKIT D816V-Gluc cells engraftment in injected mice by measurement of Gluc activity in blood and 
by IVIS. A. Gluc activity in plasma of mice after various times of engraftment. Different numbers of ROSAKIT D816V-Gluc cells [1x106 (●), 5x106 
(■) and 10x106 (▲)] were injected intravenously in mice and engraftment was monitored over time (4, 8 and 10 weeks). Each point represents 
an individual mouse. B. IVIS showing localization of Gluc in injected mice after 10 weeks. Indicated numbers of ROSAKIT D816V-Gluc cells were IV 
injected in mice (n = 6). Units in rainbow color scales are photons per second per cm2 per steradian (p/sec/cm2/sr). Results shown are from one 
representative mouse for each group. C. Total relative units (RLU) per second were calculated for Gluc intensity shown in (B) by ROI analysis 
after 10 weeks of engraftment in the three groups of mice. Each point represents an individual mouse.
Oncotarget82990www.impactjournals.com/oncotarget
Gluc cells in affected tissues (Table 2). Interestingly, the 
percentage of ROSAKIT D816V-Gluc cells in BM reached a 
plateau at 10 weeks regardless the number of ROSAKIT 
D816V-Gluc cells injected (Figure 4B and Table 2). All in all, 
the high percentages of neoplastic MCs found in BM, 
together with a moderate infiltration of the spleen and of 
the PB, might indicate that diseased animals suffer of a 
pathology similar to an aleukemic MCL, as observed in 
some human patients [28].
We then studied in detail the organs engrafted by 
ROSAKIT D816V-Gluc cells, using immunohistochemical (IHC) 
staining with antibodies directed against human tryptase 
and human CD45. Analysis of BM sections of mice 
euthanized at 10 weeks revealed the presence of fibrosis, 
especially in the group injected with 10x106 cells, as well 
as the presence of large clusters of tryptase and hCD45 
positive cells (Figure 5), consistent with the pathological 
appearance of BM biopsies in human patients with 
advanced SM [29]. Whatsoever, tryptase+ and hCD45+ 
cells were detected at a high level in BM sections but in 
a lower extent in spleen (Figure 6A) and liver sections 
(Figure 6B). In the last two organs, a few clusters of MCs 
and isolated MCs were observed in all the organ sections 
(Figure 6A and 6B).
To further confirm the relevance of our in vivo 
model of SM towards the human pathology, we measured 
serum human tryptase levels in PB of xenotransplanted 
animals at 10 weeks. Consistent with the observation that 
tryptase serum levels are elevated in SM patients [30], 
significant levels of human tryptase (ranging from > 7.0 
to > 11.0 μg/L) were measured in all xenotransplanted 
mice compared to the negative control, where the level 
of tryptase was found undetectable (< 1 μg/L) (Table 3). 
Interestingly, increased levels of serum tryptase paralleled 
increased numbers of cells injected at the beginning of the 
experiments (Table 3).
Finally, after 12 weeks of transplantation, signs of 
health deterioration appeared in mice injected respectively 
with 5x106 or 10x106 ROSAKIT D816V-Gluc cells, such as a 
decrease in water and food consumption accompanied 
with bristly hair, prostration and paralysis. This clinical 
phenotype further confirmed that the mice suffered from 
an aggressive form of the disease.
Xeno-transplanted ROSAKIT D816V-Gluc cells have 
enhanced grafting capabilities
In order to appreciate if ROSAKIT D816V-Gluc cells were 
able to retain their grafting capabilities in a secondary 
transplant model, we grafted naive irradiated animals 
with a low number of human cells purified from the BM 
of previously xenotransplanted mice. Five weeks after 
the secondary transplantation, the efficacy of engraftment 
was assessed by measurement of Gluc activity in plasma, 
assessment of whole body by IVIS, and by measurement 
of the percentage of hCD45+/hCD117+ cells in PB. As 
previously seen in the experiments of first transplantation, 
we observed that Gluc activity increased in a time-
dependent manner in the plasma (Figure 7A). In addition, 
as compared to non-injected control mouse, Gluc was 
detected by IVIS as soon as 5 weeks following the 
xenotransplantation in the majority of the mice injected 
with previously engrafted ROSAKIT D816V-Gluc cells. The 
bioluminescence was found localized mainly in femur 
and feet (Figure 7B). Of note, after 9 weeks of secondary 
transplantation, Gluc expression was considerably 
increased when measured by IVIS (Figure 7B). 
Interestingly, in mice xenografted with pre-transplanted 
ROSAKIT D816V-Gluc cells, the percentage of hCD45+/
hCD117+ cells in PB, as well as the level of Gluc activity, 
were found greater after the secondary transplantation of 
5x105 cells than after the primary transplantation of 10x106 
cells, suggesting that the first transplantation selected more 
“mice adapted” neoplastic MCs.
To evaluate more precisely the progression of the 
disease in the mice injected with previously transplanted 
cells, we measured the percentage of ROSAKIT D816V-Gluc 
cells in PB, BM and spleen after 5, 7, 8 and 9 weeks of 
secondary transplantation through the quantification of 
hCD45+/hCD117+ cells by flow cytometry. We observed 
that the percentage of ROSAKIT D816V-Gluc cells in PB 
increased significantly in a time-dependent manner 
(Figure 7C). Besides, at 9-weeks period of engraftment, 
the percentage of ROSAKIT D816V-Gluc cells was found much 
higher in BM (around 35 %) than in spleen (around 1.5 
%) or in PB (1.5 %) (Figure 7D). This observation was 
confirmed after IHC staining of human CD45 in BM, 
Table 1: Absolute numbers of ROSAKIT D816V-Gluc cells in PB of NSG mice injected with different amounts of cells
 ROSAKIT D816V-Gluc cell number in PB (x106/mL)
Groups 4 weeks 8 weeks 10 weeks
1x106 (n=6) 0 0.006 ± 0.004 0.012 ± 0.004
5x106 (n=6) 0.004 ± 0.001*** 0.021 ± 0.007* 0.025 ± 0.009*
10x106 (n=6) 0.003 ± 0.001*** 0.042 ± 0.013*** 0.039 ± 0.017*
Data are presented as mean ± SD and paired t-test was performed in comparison to the group receiving 1x106 cells.
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spleen, and liver (Figure 8). Finally, to confirm that 
secondary transplantation of the human KIT D816V+ MC 
line did not alter the expression of the mutant KIT gene, 
we explored the expression of KIT D816V mutant on BM 
cells of secondary transplanted mice using allele-specific 
RT-PCR. As shown on Figure 9A, BM cells of the two 
injected mice expressed the KIT D816V mutant, exactly as 
did the ROSAKIT D816V cell line. As expected, no expression 
of the KIT mutant was detected in control, KIT mutant-
negative ROSAKIT WT cells (Figure 9A).
Xenotransplanted ROSAKIT D816V-Gluc cells have 
advanced SM-like alterations in signaling 
pathways
In KIT D816V+ neoplastic MCs found in the BM 
of SM patients, and particularly those with advanced 
SM, KIT is found spontaneously activated, but also 
other intracellular substrates are aberrantly activated 
(phosphorylated), such as signal transducer and activator 
of transcription 5 (STAT5), AKT and extracellular signal-
regulated kinases 1/2 (ERK1/2) [31, 32]. Those signaling 
molecules have been found increasingly phosphorylated 
in parallel with the aggressiveness of the disease and 
resistance of the neoplastic MCs to TKIs [31, 32]. To 
further confirm the similarity of our in vivo model of 
KIT D816V+ advanced SM with the human situation, 
we analyzed the spontaneous phosphorylation state of 
KIT, STAT5, AKT and ERK in BM cells isolated from 
secondary injected mice, as compared to the ROSAKIT D816V 
parental cell line. As shown in Figure 9B, the constitutive 
activation of the KIT receptor was accompanied by 
aberrant phosphorylation of KIT-downstream signaling 
pathways such as AKT, STAT5 and ERK. These findings 
are consistent with those reported for neoplastic MCs in 
advanced SM patients [31].
Figure 4: Evaluation of ROSAKIT D816V-Gluc cells numbers by flow cytometry in peripheral blood, bone marrow and spleen. 
A. Percentage of ROSAKIT D816V-Gluc cells in PB after increasing times of engraftment (4, 8 and 10 weeks). The percentage of ROSAKIT D816V-
Gluc cells was determined in the three groups of mice: 1x106 (●), 5x106 (■) and 10x106 (▲) by flow cytometry using monoclonal antibodies 
against human CD45 and human CD117. B, C. Percentages of ROSAKIT D816V-Gluc cells after 10 weeks of engraftment in BM and spleen 
respectively in the three groups of mice: 1x106 (●), 5x106 (■) and 10x106(▲). Each point represents an individual mouse.
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Table 2: Absolute numbers of ROSAKIT D816V-Gluc cells in affected tissues of NSG mice injected with different amounts 
of cells after 10 weeks of engraftment
 ROSAKIT D816V-Gluc cell number (x106/mL)
Groups PB Spleen BM
1x106 (n=3) 0.012 ± 0.004 0.856 ± 0.13 4.509 ± 0.690
5x106 (n=3) 0.025 ± 0.009* 1.091 ± 0.294 3.618 ± 0.669
10x106 (n=3) 0.032 ± 0.007* 1.134 ± 0.195 4.323 ± 0.802
Data are presented as mean ± SD and paired t-test was performed in comparison to the group receiving 1x106 cells.
Figure 5: Localization of primary engrafted ROSAKIT D816V-Gluc cells in mice BM by IHC detection of tryptase and 
hCD45. Ten weeks after engraftment, BM sections from the three groups of mice were stained by IHC with an anti-human tryptase 
antibody (left and middle panels) antibody and an anti-human CD45 antibody (right panel). Staining was visualized by Histomouse Kit, 
showing human MCs in brownish staining. Magnification is x10 (left panel) and x50 (middle and right panels). Results are from one 
representative mouse from each group.
Figure 6: Localization of primary engrafted ROSAKIT D816V-Gluc cells in mice spleen and liver by IHC detection of tryptase 
and hCD45. Ten weeks after engraftment, spleen A. and liver B. sections from the three groups of mice were stained by IHC with an 
anti-human tryptase (left and middle panels) antibody and an anti-human CD45 (right panel) showing human MCs in brownish staining. 
Magnification is x10 (left panel) and x50 (middle and right panels). Results are from one representative mouse from each group.
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Figure 7: Reconstitution capacity of the human ROSAKIT D816V-Gluc cells in NSG mice after secondary transplantation. 
Ten weeks after engraftment in primary recipient mice, human cells were isolated from BM samples and injected into secondary recipient 
mice (n = 12). Engraftment was assessed 5, 7, 8 and 9 weeks after injection. A. Time-dependent increase of Gluc activity in plasma after 
secondary transplantation with ROSAKIT D816V-Gluc cells. Each point represents an individual mouse. B. In vivo imaging of Gluc activity 
in secondary injected mice (right lane) after 5 weeks (top lane) and 9 weeks (bottom lane) versus negative control (left lane). Results 
shown are from one representative mouse. C. Time-dependent increase in the percentages of ROSAKIT D816V-Gluc cells in PB after secondary 
transplantation. D. Percentage of ROSAKIT D816V-Gluc cells after secondary transplantation in PB (●), spleen (■) and BM (▲). The percentage 
of hCD45+/hCD117+ was measured using flow cytometry in C and D.
Figure 8: Localization of previously xenotransplanted ROSAKIT D816V-Gluc cells in mice BM using IHC detection of hCD45 
after secondary transplantation. BM sections (left panel), spleen sections (middle panel), and liver sections (right panel) stained by 
IHC with anti-human CD45 antibody showing human cells in brownish staining. Magnification is x10 (top lane) and x50 (bottom lane). 
Each result shown is from one representative mouse having received previously xenotransplanted ROSAKIT D816V-Gluc cells.
Table 3: Serum tryptase levels in NSG mice injected with different numbers of ROSAKIT D816V-Gluc cells
Groups Tryptase level (μg/L)
Negative control < 1.00
1x106 (n=3) 7.29 ± 1.00
5x106 (n=3) 9.17 ± 0.31*
10x106 (n=3) 11.65 ± 2.56
Data are presented as mean ± SD and paired t-test was performed in comparison to the group receiving 1x106 cells.
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DISCUSSION
SM are rare neoplasms characterized by a specific, 
recurrent and almost always acquired molecular defect 
inducing constitutive activation of the KIT receptor 
[33]. The most frequent defect found in all categories of 
SM is the KIT D816V point mutation [18]. KIT D816V 
mutant is found in > 90% of all ISM cases and in up to 
80% of advanced SM patients [34]. Recently, we have 
established a unique human MC line, termed ROSAKIT 
D816V, which is considered as the first relevant in vitro 
model of human neoplastic MCs bearing only the KIT 
D816V mutant [26]. We reported that this KIT D816V+ 
MC line is highly tumorigenic in immunocompromised 
mice, by contrast to its parental cell line presenting with a 
wild type KIT (ROSAKIT WT) [26]. However, to the best of 
our knowledge, there is no in vivo model of engraftment of 
human KIT D816V+ MCs where of the disease progression 
can be monitored repeatedly by a simple, non-stressing 
technique. Thus, we took advantage of the availability of 
our ROSAKIT D816V cell line to generate a new in vivo model 
of engraftment of human KIT D816V+ neoplastic MCs in 
NSG mice, using the Gluc reporter system, that allows to 
monitor the disease progression by a simple measurement 
in blood samples, in real time, without stressing the 
animals [27, 35].
In the first step of our work, we generated ROSAKIT 
D816V cells expressing the secreted Gaussia princeps 
luciferase [27, 35], termed ROSAKIT D816V-Gluc cells. We 
then confirmed by the measurement of Gluc activity in 
the cell supernatants that ROSAKIT D816V-Gluc cells effectively 
express Gluc, as previously reported for other cell models 
[27]. In addition, we demonstrated that lentiviral infection 
of ROSAKIT D816V cells with the Gluc-containing construct 
did not alter their morphology, the KIT D816V expression, 
the constitutive phosphorylation of the KIT receptor, and 
their SCF-independence. In addition, we demonstrated that 
the ROSAKIT D816V-Gluc cells retained the same sensitivity (or 
resistance) to different TKIs than the parental ROSAKIT 
D816V cell line, making it a very attractive tool to screen 
for new targeted drugs in vitro and in vivo. Particularly, 
as previously described in other neoplastic MC models 
[20], we confirmed the resistance of our KIT D816V+ MC 
model towards Imatinib, while the cells remained sensitive 
to Midostaurin.
With the aim to establish a new in vivo model of 
KIT D816V+ SM in which the progression of the disease 
could be easy to follow accurately, we injected various 
numbers of ROSAKIT D816V-Gluc cells in previously irradiated 
NSG mice. Expression of Gluc by injected cells allowed 
us to check and monitor accurately not only the cell 
engraftment but also the progression of SM in NSG mice. 
Indeed, we observed that, after 4 weeks following the cell 
transplantation, Gluc activity in the PB of xenografted 
animals displayed a linear relationship with the number 
of cells injected, as previously described for other in 
vivo models [27]. However, in our study, there was no 
apparent difference between the 5x106 and the 10x106 
groups at 8 and 10 weeks, suggesting that over a given 
number of cells injected, saturation is reached (Figure 3A). 
Since Gluc blood assay complements IVIS, which has the 
ability to localize the signal in organs [36], we analyzed 
Gluc expression in the whole body of the injected mice. 
Quantification through ROI analysis revealed that Gluc 
intensity was heterogeneous among groups. Comparing 
the two methods, measurement of Gluc activity in plasma 
seemed thus more reliable than measurement of Gluc 
intensity by IVIS to reflect the total MC burden in the 
animals. In conclusion, Gluc assay in PB provides both 
a sensitive and quantitative assessment of engraftment, 
complementing IVIS, which has the ability to localize the 
signal (thus the grafted cells) in different organs of the 
animals.
Figure 9: ROSAKIT D816V-Gluc cells express in vivo KIT D816V mutant leading to constitutive phosphorylation of KIT and 
of downstream signaling pathways after secondary transplantation. A. Expression of the KIT D816V gene in BM samples of 
injected mice using allele-specific RT-PCR. KIT D816V allele-specific PCR was performed using ROSAKIT D816V cells as a positive control. 
The image is an inverted form of the original picture. B. Spontaneous phosphorylation of the KIT receptor and of its downstream signaling 
pathways (STAT5, AKT and ERK) revealed by western blotting in ROSAKIT D816V cells and BM cells of secondary transplanted mice. An 
anti-human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. The lanes were run on the same gel.
Oncotarget82995www.impactjournals.com/oncotarget
Furthermore, we showed that ROSAKIT D816V-Gluc 
cells can engraft all injected NSG mice, not only at the 
BM level but also in spleen, liver and PB, giving rise 
to a SM-like disease nearing the one found in humans, 
according to the WHO criteria for the diagnosis of SM 
[37]. The percentage of ROSAKIT D816V-Gluc cells increased 
in a time- and number of cells injected-dependent manner, 
suggesting that the disease progression can be accelerated 
or slowed by varying the number of cells injected. As 
expected, the percentage of ROSAKIT D816V-Gluc cells in BM 
was found much higher than in spleen and PB, suggesting 
that ROSAKIT D816V-Gluc mainly accumulated in BM, as 
evidenced on BM sections stained for hMC tryptase and 
hCD45. However, the percentage of ROSAKIT D816V-Gluc 
cells in BM was not strictly parallel to the increase of 
total ROSAKIT D816V-Gluc cell number in mice, meaning that 
the cell number reached a plateau in the BM, while the 
cells continued to proliferate in other tissues. Whatsoever, 
the percentage of neoplastic human MCs reached 20% 
or above in the BM of injected animals. This criterion 
is diagnostic for MCL [8]. In addition, all injected mice 
presented a high level of serum tryptase (ranging from > 
7.0 ng/mL for mice injected with 1x106 cells to > 11.0 
ng/mL for mice injected with 10x106 cells), although not 
exceeding the threshold of 20 ng/mL, a value established 
for SM diagnosis in humans [8]. This may be explained 
by the relativity low content of tryptase of the ROSAKIT 
D816V-Gluc cells as compared to neoplastic MCs found in the 
BM of SM patients (data not shown). In addition, one has 
to keep in mind that, contrasting to the human situation 
where tryptase is already detectable at several ng/mL 
in the bloodstream of healthy individuals, the level of 
human tryptase in healthy mice is equal to zero. Thus, any 
increase in human tryptase level in PB of our mice reflects 
MCs engraftment. Interestingly, the level of tryptase 
in plasma was significantly correlated with the level of 
Gluc in plasma at 10 weeks (p value = 0.007 - R square = 
0.67), indicating that measuring Gluc activity in plasma 
is a reliable method to monitor disease progression in 
our in vivo model. Of note, while quantification of serum 
tryptase level required more than 50 μL of plasma, only 
5 μL of blood or plasma samples are needed to measure 
Gluc activity.
All in all, our in vivo model of primary 
xenotransplantation fits well with the one of an advanced 
(ASM/MCL-like) SM disease, a fact further confirmed by 
the rapid deterioration of the health status of the mice after 
12 weeks of engraftment. In line with this observation, it 
has to be underlined that the mean overall survival of MCL 
patients is usually very short in the absence of treatment, 
being of 6 months or less [38].
In addition, we have demonstrated that the 
transplantation of ROSAKIT D816V-Gluc cells from primary 
engrafted NSG mice into secondary recipient increased 
their capacity of engraftment. This indicates that ROSAKIT 
D816V-Gluc cells were adapted to the mouse microenvironment 
upon the first transplantation, explaining thus the 
acceleration of secondary engraftment. Such phenomenon 
has been previously shown in serial transplantations of 
other types of leukemic cells isolated from patients [39]. 
Interestingly, this enhanced engraftment capability of 
previously xenotransplanted ROSAKIT D816V-Gluc cells might 
enable us to use these cells to achieve larger lots of mice 
for preclinical studies.
Of note, the in vivo model presented here is a unique 
model paralleling human KIT D816V+ advanced SM 
disease, with many advantages over previously published 
in vivo models which did not really reproduce the clinical 
and biological characteristics of advanced SM. In fact, 
injection of the human leukemic MC line HMC-1.2 
exhibiting two KIT mutations, KIT V560G and KIT D816V 
- which is unusual in SM patients - in SCID mice, gave 
rise to solid tumors in 6 weeks to 5 months [24]. More 
recently, we have described a model of mice transgenic 
for KIT D816V, which expressed the human KIT D816V 
mutant specifically in MCs under the control of baboon 
chymase promoter [22]. However, only one third of the 
transgenic mice developed an ISM-like disease, with 
a moderate MC hyperplasia, after 12 to 24 months of 
latency [22]. In this model, the low disease penetrance 
and the delay of disease appearance made drug studies 
problematic, in addition to the fact that the KIT D816V 
mutant was expressed in murine MCs. In 2006, Demehri et 
al. have developed a murine model based on IV injection 
of P815 cells, a mouse mastocytoma cell line harboring kit 
D814Y mutant (analogue to KIT D816Y mutant in human) 
in DBA/2 mice [25]. This model gave rise to an ASM/
MCL-like disease after 6-9 days, with a severe mortality at 
9 days, making in vivo drug studies impossible to perform 
in a so short time. More recently, another transgenic mice 
model have been developed by Gerbaulet et al. using 
the Cre/loxP recombination system allowing conditional 
expression of the Kit D814V mutant (murine homolog 
of human KIT D816V mutation) under the control of the 
Kit promoter. In this model, the development of a SM-
like disease followed a slow kinetics (around 52 weeks), 
and mice developed colitis associated with mucosal MC 
accumulation [23]. Thus, this model is far from nearing 
human KIT D816V+ advanced SM as it deals with a Kit 
D814V mutant expressed in murine MCs [23].
Furthermore, compared to previous models of 
SM, our in vivo model nears at the best the biological 
characteristics of neoplastic MCs found in vivo in 
advanced SM patients. Particularly, the presence of KIT 
D816V mutant, together with the constitutive activation 
of KIT, but also of STAT5, AKT and ERK in these cells 
mimic the situation observed in such patients where 
STAT5, AKT and ERK have been found increasingly 
phosphorylated in parallel with the aggressiveness of 
the disease and its resistance to TKIs [31, 32]. Our 
model will thus help to test targeted therapies, alone or 
in combination, directed not only against the KIT D816V 
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mutant but also against other oncogenic signaling involved 
in the progression of the disease and in the resistance to 
TKIs in vivo.
In conclusion, the secretion of luciferase (Gluc) by 
our newly generated human KIT D816V+ Gluc+ neoplastic 
MC line greatly facilitates the assessment of engraftment 
in mice and allows the accurate monitoring of disease 
progression. Moreover, although MC engraftment is 
observed within 4 weeks in 100% of injected mice, 
health deterioration is observed after 12 weeks or even 
later, depending on the number of cells injected, allowing 
thus i) to increase or decrease disease aggressiveness by 
increasing or decreasing the number of injected cells and 
ii) sufficient time between the development of the disease 
and its fatal outcome, which is a critical requisite for 
easy preclinical drug studies. Such additional studies are 
ongoing in our laboratory on this model.
MATERIALS AND METHODS
Cell culture
The human parental, SCF-dependent non-
tumorigenic MC line, ROSAKIT WT was cultured exactly 
as previously described, in the presence of 10% of 
supernatant of Chinese hamster ovary (CHO) cells 
transfected with the murine SCF gene, used as a source 
of SCF [26]. The human neoplastic, SCF-independent 
tumorigenic MC line ROSAKIT D816V was obtained by stable 
lentiviral transduction of a construct encoding for the 
human KIT D816V gene and GFP in the parental ROSAKIT 
WT cell line, as already described [26] and was cultured in 
the absence of SCF, exactly as previously described [26]. 
The human MCL cell line HMC-1.2 harboring both KIT 
V560G and KIT D816V mutations (kindly provided by 
Dr. J. H. Butterfield; Mayo Clinic, Rochester, MN) was 
cultured exactly as already described [40].
Transduction of ROSAKIT D816V cells with LV-
Gluc-CFP construct
Lentivirus vector construction and production of LV-
Gluc-CFP were performed as previously described [27, 
35]. Briefly, the Gaussia luciferase cDNA was cloned into 
lentivirus vector under the control of the strong constitutive 
cytomegalovirus (CMV) promoter to produce LV-Gluc. In 
another vector, cDNA for Gluc and the optimized cyan 
fluorescent protein (CFP) separated by IRES (LV-Gluc-
CFP) were cloned under the CMV promoter. Lentivirus 
particles were produced by transfection of 293T cells as 
previously described [27]. ROSAKIT D816V cells were then 
transduced overnight with lentiviral particles of LV-Gluc-
CFP in order to produce ROSAKIT D816V-Gluc CFP+ cells. The 
efficacy of transduction was measured after 7 days by flow 
cytometry. ROSAKIT D816V-Gluc cells expressing both GFP 
and CFP were then sorted using a BD FACSAria (Beckton 
Dickinson Biosciences).
Morphological and phenotypical analysis of the 
ROSAKIT D816V-Gluc cell line
In order to ensure that lentiviral transduction of 
ROSAKIT D816V cells with LV-Gluc-CFP construct have 
not affected the morphology of the cells, May-Grünwald 
Giemsa (MGG)-stained cytospin preparations of ROSAKIT 
D816V and ROSAKIT D816V-Gluc cells were examined using a 
Zeiss Axiophot microscope (Carl Zeiss). In addition, 
the expression of KIT (CD117) was analyzed on both 
cell lines cells by direct immunofluorescence using a 
FACSCalibur (BD Biosciences). Briefly, 2x105 untreated 
cells were incubated with APC (allophycocyanin)-
labeled monoclonal antibody directed against human 
CD117 (BioLegend). Isotype control was used for each 
experiment, and at least 10,000 events were recorded on a 
BD FACSCalibur.
Allele specific RT-PCR for the detection of the 
KIT D816V mutant
Total RNA from 5x106 ROSAKIT WT cells, ROSAKIT 
D816V cells, ROSAKIT D816V-Gluc cells, HMC1.2 cells, or from 
5x105 human cells purified from BM of mice previously 
xenografted with ROSAKIT D816V-Gluc cells was isolated 
using TRIzol (Life Technologies) or using Nucleospin 
RNA (Machery Nagel) according to the manufacturer’s 
protocol. RNA concentration and purity was determined 
using a Nanovue plus spectrophotometer (GE Healthcare). 
Starting from these RNA samples, first strand cDNA 
synthesis was conducted using the iScript Select cDNA 
synthesis kit (Biorad) or using Superscript II reverse 
transcriptase (Invitrogen) according to the manufacturer’s 
instructions. PCR was performed using primer sequences 
designed as described by Kristensen et al. [41]: a forward 
primer 5’-AGAGACTTGFCAGCCAGAAAA-3’, and a 
reverse primer 5’-TTAACCACATAATTAGAATCATTC
TTGATCA-3’ for KIT D816V. Reactions were compared 
to levels of the hypoxanthine phospho-ribo-transferase 
(HPRT) amplified using the following primers: HPRT F; 
5’-ATGGACAGGACTGAACGTCTTGC-3’; and HPRT 
R; 5’-GACACAAACATGATTCAAATCCCTGA-3’. 
Complementary DNA were amplified using the following 
cycle conditions: 95°C for 10 min, followed by 40 cycles 
of 95°C for 15 s, 60°C for 1 min and 72°C for 1 min. 
All PCR experiments included a no template control 
(water). The amplified PCR products were visualized by 
staining with ethidium bromide (Electran) after 1.5 % 
agarose gel electrophoresis in Tris–acetate–EDTA buffer 
(Euromedex).
Western blot analysis for KIT signaling
Western blots were performed on cell lysates 
from ROSAKIT WT cells stimulated with SCF, or from 
unstimulated ROSAKIT D816V and ROSAKIT D816V-Gluc cells, 
using an antibody against phosphorylated KIT Y719 
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(Cell Signaling Technology), in order to visualize the 
phosphorylation state of KIT. Western blots were also 
performed on lysates of mouse BM cells using antibodies 
against phosphorylated KIT Y719, phosphorylated STAT5 
Y694, phosphorylated AKT S473 and phosphorylated 
ERK Y202/204 (all from Cell Signaling Technology). 
Proteins were visualized with horseradish peroxidase-
conjugated secondary antibodes and chemoluminescent 
substrate (Promega). A mouse monoclonal IgG1 anti-
human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) Ab (Santa Cruz Biotechnology) was used as a 
loading control.
In vitro gluc activity assay
To measure Gluc activity in cell supernatant, 
ROSAKIT D816V cells expressing or not Gluc were seeded 
in 24-well plates at various concentrations (from 100 to 
1x106 cells/mL) and incubated for 24 hours at 37°C and 
5 % CO2. Twenty microliters of conditioned medium 
were assayed using 100 μL (5 μg/mL) water-soluble 
coelenterazine (CTZ) (Nanolight Technologies) in full 
white plates. Photon counts were acquired immediately 
using a luminometer (PerkinElmer - EnSpire®).
Analysis of the effects of TKIs on cell 
proliferation
To ensure that lentiviral transduction of ROSAKIT 
D816V cells with LV-Gluc-CFP construct has not 
influenced the sensitivity of the cells towards different 
TKIs, the effect of Imatinib (Sequoia Research) and 
of Midostaurin (Novartis Pharmaceutical Corporation) 
on cell proliferation was measured using the 3-(4, 
5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) test. ROSAKIT D816V and ROSAKIT D816V–Gluc cells were 
incubated with Imatinib or Midostaurin (1 nM to 10 μM) 
in 96 well plates (Falcon) at 37°C for 72 hours. After 
incubation, 20 μl of MTT (5 mg/mL) (Life technologies) 
were added in each well and the plates were incubated 
for 3 additional hours at 37°C. Then, 100 μl of acidified 
isopropanol were added to each well to dissolve formazan 
crystals. The number of living cells was then measured 
in each condition by reading the absorbance at 570 nm 
using a plate reader (Thermo-Labsystems). Results were 
expressed in % of living cells as compared to the control 
(untreated cells).
Xenogeneic transplantation of ROSAKIT D816V-Gluc 
cells in NOD-SCID IL-2R γ-/- (NSG) mice
NSG mice were bred and maintained under specific 
pathogen-free conditions at the animal facility of Gustave 
Roussy Institute. Animal experiments were performed in 
accordance with guidelines established by the Institutional 
Animal Committee.
Increasing amounts of ROSAKIT D816V-Gluc cells 
(1x106, 5x106 or 10x106) were injected to mice (3 groups; 
6 mice per group) 24 h after irradiation at 2.5 Gy from 
a cesium-137 source. Engraftment was assessed after 
4, 8 and 10 weeks using quantitative measurement of 
Gluc activity in plasma, and quantitative measurement 
of hCD45+/hCD117+ cells in PB using flow cytometry. 
After 10 weeks, in vivo bioluminescence imaging was 
performed on engrafted mice. KIT wild type (ROSAKIT 
WT control cells) were not included in this study as a 
control because they hardly - if not at all - graft in mice, as 
described elsewhere [26].
Secondary transplantations
Secondary transplantations were performed using 
human cells isolated from the BM of mice previously 
injected with ROSAKIT D816V-Gluc cells. Briefly, after 10 
weeks of engraftment, one femur and two tibias were 
recovered from each animal and flushed in 1 mL of PBS. 
BM cells were then purified using EasySep™ Mouse/
Human Chimera Isolation Kit (Stem Cell) according to 
the manufacters’ instructions. Purified BM cells were then 
pooled, and 5x105 cells were IV injected to each NSG 
mouse (n = 12) 24 h after their irradiation at 2.5 Gy from 
a cesium-137 source.
Flow cytometry analysis for the detection of 
xenografted cells
ROSAKIT D816V-Gluc cells were quantified in mouse 
PB, BM and spleen samples by flow cytometry using PE-
labeled monoclonal antibodies (mAb) directed against 
human CD117 (Beckman Coulter), PE-Cy7- labeled 
hCD45 and APC-labeled mCD45 (BD Biosciences). 
Engrafted ROSAKIT D816V-Gluc cells were defined as hCD45+/
CD117+ cells.
Measurement of gluc activity ex vivo in 
peripheral blood
Blood samples were collected in EDTA pre-coated 
vials (KABE Labortecknik). Gluc activity was determined 
on 5 μl of plasma by adding 100 μl of water soluble CTZ 
(50 μg/mL) followed by immediate acquisition of photon 
counts using a luminometer (PerkinElmer - EnSpire) as 
previously described by Morse and Tannous [42].
In vivo bioluminescence imaging
Mice were anesthetized using isoflurane and Gluc 
imaging was performed immediately after IV injection 
of 100 μl water soluble CTZ (4 mg/kg body weight) 
using a CCD camera (IVIS 50) and analyzed with 
Living Image® Software as previously described [42]. 
Quantitative analysis of Gluc intensity was performed 
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by measuring luminescence signal intensity using region 
of interest (ROI) setting of the Living Image® software. 
ROIs were placed around the total area of body mice. ROI 
measurements were expressed as total flux (p/s).
Histopathology and immunohistochemistry 
(IHC) analysis
Deparaffinized sections of BM, spleen and liver 
processed for heat-induced antigen retrieval were 
incubated with a mouse anti-human CD45 mAb (Dako) 
or with a mouse anti-human MC tryptase (Dako). 
Staining was visualized by Histomouse Kit (Zymed). 
The sections were then counterstained with hematoxylin 
and examined using a Zeiss Axiophot microscope (Carl 
Zeiss).
Serum tryptase measurement
Total serum tryptase was measured using 
fluorescent enzyme-linked immunoassay that detects 
specifically human tryptase, following the manufacturer’s 
recommendations (Unicap Pharmacia) [43]. The detection 
limit of this assay is 1 ng/mL, and in human healthy 
controls, serum tryptase levels range between less than 
1 and 15 ng/mL, with a median of approximately 5 ng/
mL [44].
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism 5.03 software. Data were analyzed using a two 
tailed Student’s t test. The levels of significance were as 
follow: *, p<0.05; **, p<0.01; ***, p<0.001.
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